Evaluation of the Risk of Clinical Deterioration among Inpatients with COVID-19

Table 1

Demographic data of the studied sample.

	Place of hospitalization		value
	Hosp_Intern (n = 59)	ICU (n = 15)
Descriptive data
Age	47.9 (±SD:16.5)	66.5 (±SD: 17.3)	0.001
Sex (male)	35 (47.3)	12 (16.2)	0.137
White ethnicity	40 (70.1)	9 (15.7)	0.696
Patient is a healthcare professional (yes)	13 (18.0)	1 (1.3)	0.276
Patient had contact with grippal syndrome (yes)	24 (32.4)	4 (5.4)	0.741
Received flu vaccine during the last campaign (yes)	21 (42.8)	6 (12.2)	0.488
Not being a resident of the city (Juiz de Fora)	10 (13.5)	6 (8.1)	0.077
Comorbidities
Hypertension	20 (27.0)	9 (12.2)	0.064
Diabetes	4 (5.4)	0 (0.0)	0.300
Dyslipidemia	0 (0.0)	1 (1.4)	0.203
Immunosuppression	2 (2.7)	0 (0.0)	0.470
Cardiopathy	4 (5.4)	4 (5.4)	0.048
Asthma	1 (1.4)	0 (0.0)	1.000
COPD	0 (0.0)	2 (2.7)	0.039
Symptoms on admission
Tachypnea	45 (62.5)	7 (9.7)	0.051
Tachycardia	12 (16.6)	3 (4.1)	0.929
Cough	47 (63.5)	9 (12.2)	0.175
Dyspnea	21 (28.4)	6 (8.1)	0.752
Odynophagia	17 (23.0)	0 (0.0)	0.016
Sputum production	1 (1.4)	1 (1.4)	0.367
Headache	13 (17.6)	2 (2.7)	0.791
Fever	44 (59.5)	10 (13.5)	0.531
Rhinorrhea	14 (18.9)	2 (2.7)	0.499
Diarrhea	13 (17.6)	3 (4.1)	0.864

SD: standard deviation; n (%); values were calculated by the Mann–Whitney U test, χ2 test, or Fisher’s exact test.